Press coverage about Proteon Therapeutics (NASDAQ:PRTO) has been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Proteon Therapeutics earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.0140145404177 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Proteon Therapeutics stock remained flat at $$2.45 on Friday. 24,699 shares of the company’s stock traded hands, compared to its average volume of 40,008. The company has a market cap of $43.30, a PE ratio of -1.15 and a beta of 1.51. Proteon Therapeutics has a 52 week low of $1.10 and a 52 week high of $2.85.
Proteon Therapeutics (NASDAQ:PRTO) last issued its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.14. research analysts forecast that Proteon Therapeutics will post -1.44 earnings per share for the current year.
Several research analysts recently weighed in on PRTO shares. Zacks Investment Research upgraded shares of Proteon Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 4th. Robert W. Baird set a $3.00 target price on shares of Proteon Therapeutics and gave the company a “hold” rating in a research report on Wednesday, March 14th. Finally, HC Wainwright set a $2.00 target price on shares of Proteon Therapeutics and gave the company a “hold” rating in a research report on Friday, March 16th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Proteon Therapeutics presently has a consensus rating of “Hold” and an average price target of $3.38.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.